Dysfunction of the prefrontal cortex (PFC) is considered to be an important factor contributing to a decrease in cognitive performance of schizophrenia patients. The medial PFC (mPFC) is innervated by the hippocampus/subiculum, and the subiculum-mPFC pathway is known to be involved in various cognitive processes. Glutamate-containing subicular axons innervate cortical pyramidal neurons and interneurons where AMPA and NMDA receptors are implicated in synaptic transmission. In our experiments, properties of subiculum-mPFC interactions were studied using pathway stimulation and local field potential (LFP) recordings of the mPFC in urethane-anaesthetized rats. Changes in paired-pulse facilitation (PPF) and LFP oscillations, effects of the NMDA receptor antagonist MK-801, and the AMPAkine LY451395 were evaluated. Effects of disruption of the thalamo-cortical loop with local microinjection of lidocaine into the mediodorsal thalamic nucleus (MD) were also studied. Our findings demonstrate that both systemic administration of MK-801 and local MD lidocaine microinjection produce similar changes in LFP oscillations and reduction in PPF. Specifically, it was observed that MK-801 (0.05 mg/kg i.v.) and intra-thalamic lidocaine changed regular, 2 Hz delta oscillation to a less regular 0.5-1.5 Hz delta rhythm. Concurrently, PPF in response to electrical stimulation of the subiculum was significantly attenuated. Administration of the AMPAkine LY451395 (0.01 mg/kg i.v.) reversed the MK-801-and lidocaine-induced changes, and was itself blocked by the AMPA receptor antagonist CP-465022. Analysis of our findings suggests a critical role of cortical interneurons in NMDA/AMPA receptor-mediated changes in thalamo-cortical oscillations and PPF, and contributes to our understanding of the NMDA hypofunction model of schizophrenia.
Introduction
Current neuropathological and genetic studies of schizophrenia indicate abnormalities in synaptic plasticity and cortical neuronal network connectivity and in particular, a dysfunction in NMDA receptor (NMDAR)-mediated glutamate neurotransmission. Thus, in schizophrenia patients, reduced markers of glutamatergic neurotransmission have been demonstrated, together with several affected genes such as neuregulin, ERBB4, dysbindin or D-amino acid oxidase (G72) which are known to regulate glutamatergic and NMDAR function (Harrison & West, 2006 ; Tsai et al. 1995) . These findings are supported by pharmacological observations, since NMDAR antagonists like ketamine or phencyclidine (PCP) induce neuropsychological deficits in healthy volunteers resembling those of schizophrenia Krystal et al. 1994) .
Based on these findings, there is an interest in developing preclinical models of schizophrenia by inducing NMDA hypofunction. Acute administration of NMDAR antagonists to rodents interact with various CNS functions, from simple motor tasks to high level cognitive tasks. For example, it has been suggested that hyperlocomotion in rats induced by subanaesthetic doses of NMDAR antagonists, e.g. PCP or MK-801, corresponds to psychotic symptoms of schizophrenia, and can be antagonized in part by typical and atypical antipsychotic drugs (Jentsch & Roth, 1999) . Although different NMDA antagonists might show somewhat different profiles in behavioural tests, they all disrupt cognition at the lowest pharmacologically active dose (Abi-Saab et al. 1998 ; Newcomer et al. 1999) . These observations are particularly relevant since cognitive impairment in schizophrenia is considered to be most closely associated with NMDAR dysfunction (Goff & Coyle, 2001 ; Javitt, 2007) . Accordingly, numerous behavioural and electrophysiological studies have been performed in order to understand the mechanisms of cognitive impairments elicited by NMDAR antagonists. For example, recent in-vivo electrophysiological studies have disclosed how NMDAR blockade disrupts normal cortical neuronal activity and leads to disinhibition of cortical pyramidal neurons, demonstrating that systemic administration of MK-801 decreases the activity of putative GABA interneurons but increases the firing of the majority of pyramidal neurons in the prefrontal cortex (PFC) of awake rats (Homayoun & Moghaddam, 2007) . Furthermore, dysfunction of the PFC is considered to be an important factor contributing to working memory-related decrease in cognitive performance of schizophrenia patients. The PFC, and the medial PFC (mPFC), in particular, are innervated by the hippocampus/ subiculum, and the subiculum-mPFC pathway is known to play a role in cognitive processes including attention and working memory and is capable of undergoing both long-term and short-term synaptic plasticity (Kawashima et al. 2006 ; O'Mara et al. 2000 ; Rocher et al. 2004) . However, the hippocampus-mPFC system is part of a broader network of brain areas serving these functions together (Constantinidis & Procyk, 2004) . Specifically, the thalamus is an important subcortical structure, which, due to its central location, might be in a position to facilitate communication in cortical regions (Goldman-Rakic, 1998) . In particular, the mediodorsal nucleus of the thalamus (MD) seems to have major anatomical (Pirot et al. 1994 ) and functional (Watanabe & Funahashi, 2004 ; Hull et al. 2009 ) connections with the mPFC, and thus could exert a strong effect on neural activity in the mPFC.
In our present study, we analysed the effects of NMDAR antagonists on spontaneous activity of the mPFC, and paired-pulse facilitation (PPF) in the mPFC in response to electrical stimulation of the subiculum in anaesthetized rats. In addition, effects of disruption to the thalamo-cortical loop by local microinjection of lidocaine into the MD were studied with the same parameters. Considered as a potential pharmacological assay, the efficacy of the AMPA receptor potentiator LY451395 has been evaluated on cortical dysfunctions induced by either NMDAR blockade or inhibition of the thalamo-cortical pathway.
Materials and methods

Animals and surgical procedures
Experiments were performed on male SpragueDawley rats (Harlan, USA ; weighing 250-320 g) under urethane anaesthesia (1.5 g/kg i.p.). Surgical procedures were conducted in accordance with an approved animal use protocol in compliance with the Animal Welfare Act Regulations and with the Guide for the Care and Use of Laboratory Animals, National Institutes of Health guidelines. The femoral vein was cannulated for administration of drugs. The anaesthetized rat was placed in a stereotaxic frame, and craniotomies were performed above the region of the mPFC and ipsilateral CA1/subiculum. Body temperature of the rat was maintained at 37 xC by means of a thermostatically controlled electrical heating pad (Harvard Apparatus, USA). After the conclusion of the experiments animals were euthanized with an i.v. bolus of urethane.
Electrophysiological recordings
Local field potentials (LFPs) were recorded by a metal monopolar macroelectrode placed into the mPFC region (coordinates : 3.0 mm anterior from bregma, 0.6 mm lateral, 5.0 mm ventral ; Paxinos & Watson, 1986) . Field potentials were amplified, filtered (0.1-100 Hz), displayed and recorded for online and offline analysis (Spike2 software, Cambridge Electronic Design Ltd, UK). Online electrically evoked responses distinguished in the LFP and quantitative EEG analysis were performed by means of waveform averages and fast Fourier transformation. Delta power spectrum density of LFP was calculated between 0.1 and 4 Hz. In experiments with lidocaine microinjections (see below) an identical recording electrode was placed in the contralateral mPFC (coordinates : 3.0 mm anterior from bregma, x0.6 mm lateral, 5.0 mm ventral ; Paxinos & Watson, 1986 ) and data were recorded as described above.
Paired-pulse stimulus and waveform averages
A twisted-wire stimulation electrode was place in the CA1/subiculum (coordinates : 6.3 mm posterior from bregma, 5.2 mm lateral and 8.0 mm ventral ; Paxinos & Watson, 1986) . The paired-pulse stimulus consisted of two square-pulses, duration 0.1 ms, 0.1-1 mA, paired-pulse interval 100 ms, inter-stimulus interval 10 s, generated continuously from a Master 8 stimulator (APMI, USA). Intensity of stimulus was adjusted so that size of the negative component following the first stimulus (N27 1 ) was y100 mV.
Localized lidocaine microinjections
In addition to the recording and stimulating electrodes placed in the ventral mPFC and ipsilateral subiculum of the hippocampus, respectively, a lidocaine cannula was placed in the ipsilateral MD. Ten-minute baseline cortical LFP activity, and corresponding N27 1 and N27 2 (negative component following the second stimulus) response amplitudes were recorded. Animals were subsequently infused with 5 % lidocaine unilaterally via a 30-gauge stainless-steel cannula placed in the MD (coordinates from bregma : 2.3 mm posterior, 0.8 mm lateral, 6.0 mm ventral ; Paxinos & Watson, 1986) ipsilateral to stimulated subiculum. A microdialysis infusion pump (WPI SP101i) and a 250-ml Hamilton syringe were used to infuse at the rate of 1 ml/min for 2 min. A 10-min period was then measured for lidocaine effects on bilateral cortical LFP delta and PPF. All animals were subsequently treated i.v. with LY451395 (0.01-0.03 mg/kg, cumulative) and changes in LFP delta activity and PPF were determined.
Drug solutions
MK-801 (hydrogen maleate ; Tocris no. 0924, UK) was made up as a 0.05 mg/ml solution in saline. Lidocaine (hydrochloride monohydrate ; Sigma, USA) was made up as a 5 % solution in saline. The AMPAkine LY451395 (Jhee et al. 2006 ) was made up initially as a 1 mg/ml solution in 5 % DMSO, 5 % Cremaphor and 90 % hydroxypropyl-beta-cyclodextrin (HPBC) (20 % in ASterile H 2 O) (Cavitron 82003, USA) then serially diluted with HPBC until the final volume of each cumulative i.v. dose equalled 1 ml/kg. The AMPAkine dose used in the experiments was established based on its dose-response characteristics ( Supplementary Fig. S1 ). The AMPA antagonist CP-465022 (Menniti et al. 2003) was synthesized in-house at Pfizer Global Research laboratories. The drug was solubilized in 20 % HPBC at a concentration of 1 mg/ ml. The injection volume was 1 ml/kg.
Data analysis
PPF
Two PPF definitions were compared. First, PPF was defined as the ratio of the amplitude of the first evoked response and the second evoked response : A 2 /A 1 . Second, as the ratio of the slopes of the EFP while it reached its minimum following stimulation : (A 2 /t 2 )/ (A 1 /t 1 ). The two measures were found to correlate with each other in all cases (data not shown), thus only the first measure is reported below. Experiments where the PPF in controls was <1.5 were rejected from the analysis.
Numerical analysis
For offline data analysis, LFP data was read into MATLAB 1 software [version 7.5.0 (R2007b) ; The Mathworks, USA,] using the sigTOOL toolbox (Lidierth, 2009) . For data epoching, filtering and time-frequency decomposition, the EEGLAB Matlab toolbox (Delorme & Makeig, 2004) was used, while other operations were performed by self-created scripts. All statistical analysis and line fitting were performed in R (R Development Core Team, 2008) . Skewness values of a vector x in the paper are the biascorrected beta estimates of the sample skewness defined as
, where m 3 is the sample third central moment and m 2 is the sample variance.
Results
The NMDAR antagonist MK-801 disrupts regular delta activity and decreases PPF in the mPFC Control recordings of LFPs from the mPFC in urethane-anaesthetized rats (n=26) were characterized by a predominant delta-band oscillation, showing 86¡2 % of the signal power within the 0.1-4 Hz range (Fig. 1) . In order to quantify signal power distribution within the delta band, relative power was determined at low (0.1-1.5 Hz) and high (1.5-2.5 Hz) delta bands. In the control condition, the peak frequency of delta oscillation fell in the 1.5-2.5 Hz frequency range and delta power was distributed between the low-and high-delta ranges as 28¡4 % and 61¡4 %, respectively, as determined in a 600-s time-interval. Systemic administration of the non-competitive, use-dependent NMDAR antagonist MK-801 (0.05 mg/kg i.v., n=26) produced a long lasting (see Supplementary Fig. S2 ) change in the LFP profile with a short latency (<1 min). Most of the signal power was shifted into the low-delta range, although in some animals the high delta peak was still observable. Power relative to the total delta-band power was distributed between the low-and the high-delta range as 58¡4 % and 34¡3 %, respectively (power in the delta band was 93.2¡0.7 % of the total power), and changes in signal power distribution induced by MK-801 were significant (two-tailed, paired t test, p<0.001). In order to further characterize the LFPs, amplitude histograms were plotted which revealed that while in the control condition positive and negative LFP values were symmetrically distributed, as measured in the 600-s time window. However, the LFP amplitude values of MK-801-treated animals, collected for 600 s after MK-801 application, were asymmetrical where it was more likely that the LFP amplitude took positive than negative values (Fig. 1 ). The latter property was characterized by the skewness of the amplitude distributions, which yielded 0.03¡0.09 (n=26) for controls and x0.6¡0.1 (n=26) following MK-801 treatment. In controls, the skewness mean was not significantly different from 0, while after MK-801 administration it was significantly negative (one-sample t test, p<0.001), indicating that the mass of the distribution is concentrated on the right side compared to the normal distribution in the case of drug-treated animals. In a subset of experiments, the non-competitive NMDAR antagonist PCP was evaluated using the same parameters. PCP (0.25 mg/kg i.v., n=6) produced the same quantitative effects on LFP delta oscillations as MK-801 (data not shown). In addition to recording spontaneous LFPs, evoked field potentials (EFPs) were captured in response to electrical stimulation of ipsilateral subiculum in the same set of experiments (see the Materials and Methods section for details). A typical example of an EFP is depicted in Fig. 2 ; EFPs shown and used for statistical calculations are the averages of 60-200 LFP traces. The EFP measured in the mPFC consisted of a small positive deflection with a latency of y12 ms (P12 1 ) in response to the first stimulation pulse (S 1 ), which was observable as a clear-cut peak in 18/26 rats only, depending on the exact stimulating and recording electrode placements. However, a change in the slope of the LFP following the stimulation artifact after about 12 ms was always observable. This positive peak was followed by a pronounced negative peak with y27 ms latency (N27 1 ) and another positive deflection at about 40 ms (P40 1 ), which was similar to the P12 1 peak in that it was observed as a full local maximum in a few rats only. As described in earlier studies of the subiculm-mPFC pathway (Laroche et al. 1990 ; Characteristics of the medial prefrontal cortex local field potential (LFP) in the control condition after MK-801 administration and following reversal by the AMPAkine LY451395. In the control condition the LFP is characterized by a regular, y2-Hz frequency delta oscillation (determined in a 600-s time-interval). The amplitude histogram shows a symmetric distribution of amplitudes characteristic to noisy signals with a continuous frequency spectrum. Intravenous (i.v.) administration of MK-801 increases the total signal power, shifts the power peak to about 1 Hz and distorts the amplitude histogram showing that the LFP takes mostly positive values, as measured in a 600-s time window following MK-801 application. These effects are reversed by the i.v. application of the AMPAkine LY451395 (measured in a 600-s time window after administration of the AMPAkine). For the amplitude histograms the occurrence of a given raw signal value was counted and binned into 100 amplitude bins between the extreme values. Mulder et al. 1997 ) the tail of the EFP following subiculum stimulation increases slowly, starting with a latency of about 70 ms. Following S 2 , the EFP showed similar characteristics as after S 1 ; however, due to the increasing tail of the EFP following S 1 , in the control condition the baseline of the EFP before S 2 was higher than before S 1 . Moreover, the tail of the EFP was fully observable, showing a slow increase after about 70 ms following S 2 and lasting for y400-500 ms.
Systemic administration of MK-801 (0.05 mg/kg i.v., n=26) also modified the properties of the EFPs in several ways. Amplitude of the N27 1 response was significantly increased by 2-fold (one-tailed paired t test, p<0.001), while the amplitude of N27 2 was slightly (1.12 times ; although significantly p<0.003) increased, resulting in a significant decrease of the PPF of the N27 response from 2.9¡0.2 to 1.23¡0.04 (p<0.001). The latency of N27 1 significantly increased (p<0.001), while the latency of the N27 2 negative deflection did not change in response to MK-801 administration. These results are summarized in Table 1 . Note that after drug administration the latency of N27 1 did not differ significantly from the latency of N27 2 .
MK-801 administration also impacted properties of P12 1 positive deflection : the amplitude of P12 1 decreased significantly (p<0.001) to almost one-half of the control amplitude, and its latency also decreased significantly (p<0.005). However, there were no significant changes in P12 2 properties after MK-801 administration (Table 2 ). In addition, quantitative results obtained after PCP (0.25 mg/kg i.v., n=6) administration were similar to those described above (data not shown).
The concomitant changes in LFP and EFP following MK-801 administration can be visualized by showing the temporal evolution of the characteristic frequencies of the LFP and the unitary PPFs, i.e. the PPFs resulting from a single paired-pulse stimulation. Figure 3 shows a typical experiment. During the control condition the ongoing activity is characterized by an oscillation with a clear-cut frequency in the high delta band. This LFP profile is rapidly changed by MK-801 administration, producing low-frequency, broad-band oscillation, in addition to high delta frequency activity, in the delta band. Unitary PPFs change parallel with the LFP. In controls, the running average represented by a red line on Fig. 3 shows high PPF values, which rapidly decrease after MK-801 administration. All the above changes in cortical activity induced by systemic administration of MK-801, including shift in cortical delta activity and PPF, were sustained over a 1-h period following vehicle treatment (n=5, data not shown).
The above is further summarized by plotting PPF values vs. the power of the signal contained in the low delta frequency band obtained from all of our experiments (Fig. 4 a) 
Values are given as mean¡S.E.M., n is the number of EFPs used. * Denotes significant change relative to controls (paired, one-tailed t test) ; for p values see text. are smaller than control PPF values, while the power content of the signal is more pronounced in the lower delta band after MK-801 administration than in controls. Accordingly, a linear fit to all data-points shows that an increasing, relative low delta power significantly coincides with reduced PPF. It should be noted that LFP and parallel PPF change characteristics induced by MK-801 were occasionally observed in the control condition, when the anaesthetized animals spontaneously shifted into a brain state similar to the MK-801-induced condition for a short period, and returned to the normal control state afterwards (Fig. 5 ).
Thalamic microinjection of lidocaine mimics the effects of MK-801 in the mPFC
In order to disrupt the thalamo-cortical activity, lidocaine was micoinjected into the MD ipsilateral to mPFC recording and subiculum stimulation. Lidocaine microinjection altered cortical LFP recorded from the side ipsilateral to the microinjection in a similar way to those observed after MK-801 administration (Fig. 6) ; however, no significant change in contralateral LFP was observed ( Supplementary  Fig. S3 ). Specifically, the regular delta oscillation present at baseline (total delta 94¡1 %, low delta 46¡4 %, high delta 47¡4 %, n=15) was replaced in the ipsilateral recordings by a slower, low delta oscillation (total delta 97.6¡0.1 %, low delta 80¡2 %, high delta 17¡1 %, n=15) after lidocaine microinjection. Both the increase of low delta power and the decrease of high delta power were found to be significant (paired, two-tailed t tests, p<0.001 for both). Moreover, the amplitude distribution became skewed. In the control condition the skewness was not significantly different from 0 (p=0.9, n=15), while after lidocaine microinjection the amplitude distribution became leftskewed (having a heavy left tail, and probability mass shifted to the right, with skewness x0.54¡0.05, p<0.0001, n=15).
During control recordings, properties of the EFPs were identical to those described in the previous section. Lidocaine microinjection, parallel to changing spontaneous LFPs, significantly altered EFPs and PPF in the ipsilateral mPFC, without changing PPF values measured in the contralateral mPFC ( Supplementary  Fig. S4 ). In the ipsilateral side lidocaine significantly (p<0.001) increased the amplitude to S 1 response by 2.2 times, while response to S 2 did not change significantly. Thus, as a result, the PPF measured in the control condition decreased from 3.8¡0.8 (n=11) to 1.5¡0.2 (n=11) with lidocaine, and the difference was significant (p=0.02). Lidocaine application significantly increased latency of both N27 1 (p<0.001) and N27 2 (p=0.03). These results are summarized in Table 3 .
The P12 component of the EFPs were also evaluated. In contrast to the case of MK-801 administration, local lidocaine microinjection did not significantly modify the properties of either P12 1 or P12 2 (Table 4) .
After lidocaine microinjection, similar to MK-801 administration, the shifting of the signal power in the cortical delta band and the decrease of PPF occurred simultaneously (Fig. 4 b) . Indeed, a linear fit of all datapoints showed that with increasing low delta power the PPF decreased significantly (p<0.01).
Reversal of cortical effects of MK-801 and lidocaine by the AMPAkine LY451395
The effects of the selective AMPAkine compound LY451395 was evaluated on changes in cortical activity induced by MK-801 administration or thalamic lidocaine microinjection. Systemic administration of LY451395 (0.01 mg/kg i.v.) significantly reversed the increase in the low delta component of the LFP and the decrease in PPF induced by MK-801 administration (n=6 ; Fig. 7 ). Furthermore, changes in both cortical delta activity and PPF following lidocaine microinjection were also significantly reversed by LY451395 (0.01 mg/kg i.v., n=5). Increases in PPF were due predominantly to a reduction in the amplitude of N27 1 while there were no changes or even an increase in N27 2 in the lidocaine and the MK-801 models, respectively. As indicated in Fig. 3 , the effect of the AMPAkine LY451395 was delayed (the average¡ S.E.M. of this delay was 430¡70 s in the MK-801 experiments and 420¡70 s in the lidocaine experiments) ; however, after this period the reversal was instantaneous and complete including both LFP and PPF. Furthermore, the skewed distribution of the amplitude in both cases was reversed to the symmetrical control distribution (Figs 1 and 6 ).
AMPA antagonist CP-465022 blocks reversal effect of AMPAkine
The AMPAR antagonist CP-465022 was tested on the reversal effect of AMPAkine on cortical changes induced by systemic administration of MK-801. MK-801 (0.05 mg/kg i.v., n=6) induced similar significant changes as described above, including the shift in cortical delta activity (low delta power increased from 32¡7 % in controls to 69¡4 % after MK-801 administration) and decrease in PPF (controls : from 2.5¡0.3 to 1.2¡0.1 after MK-801 administration).
Neither the changed delta frequency profile nor PPF in the mPFC was significantly modified by i.v. administration of CP-465022 (1 mg/kg i.v., n=6) after treatment by MK-801 (see Fig. 8 for a typical example) . In some animals a decrease in the frequency of the remaining high delta component was observed without a change in the PPF. More specifically, low delta power increased from 69¡4 % following MK-801 treatment to 75¡4 % after subsequent CP-465022 administration. However, the AMPAR antagonist CP-465022 (1 mg/kg i.v., n=6) totally blocked the reversal effects of the AMPAkine LY451395 (0.01 mg/kg i.v.). Thus, low delta power remained at 62¡6 % after AMPAkine injection, which represented a significant increase relative to controls (p<0.05). Similarly, PPF decreased from its control value of 2.5¡0.3 to 1.2¡0.1 with MK-801, and to 0.96¡0.08 after CP-465022 treatment, remaining at 1.4¡0.3 after AMPAkine administration.
Discussion
The aim of the present study was to evaluate the subiculum-mPFC pathway as a potential substrate for studying NMDAR hypofunction of schizophrenia. Our findings demonstrate that systemic administration of MK-801, a non-competitive NMDA antagonist significantly changed cortical EEG delta activity and concomitantly reduced PPF elicited by electrical stimulation of the subiculum in urethaneanaesthetized rats. Both the shift of delta power distribution to lower frequencies and reduction of PPF following MK-801 administration were reversed by systemic administration of the AMPAkine LY451395, an effect blocked by the selective AMPAR antagonist CP-465022. The present findings suggest a critical role of NMDA and AMPA receptors in cortical delta oscillations and PPF, and provide a novel preclinical model for studying NMDA hypofunction of schizophrenia.
Monosynaptic projection from the hippocampus/ subiculum to the mPFC is well characterized, transferring oscillatory field potentials between the two regions and contributing to novelty detection and working memory (Goldman-Rakic, 1994 ; Knight & Nakada, 1998) . In the present study, rats under urethane anaesthesia showed predominant delta-band EEG activity in the mPFC typified with a regular, 2 Hz oscillation (high delta activity). Although systemic administration of MK-801 shifted this highly regular delta activity to a broader, low-frequency delta activity, relative total delta power of LFP did not change. Application of a different non-competitive NMDAR antagonist PCP induced the same changes in cortical LFPs, shifting higher power distribution from the high to low delta range (see also Sebban et al. 2002) . These findings are in contrast to recent observations demonstrating desynchronized EEG and a significant reduction in delta power following the NMDAR antagonist PCP (Kargieman et al. 2007 ). However, the fact that different types of anaesthetics were used in the previous and current studies could provide an explanation for this discrepancy. It is known that cortical oscillations at normal conditions are maintained and shaped by several neuron populations. Cortico-thalamic and thalamo-cortical projecting neurons, as well as inhibitory neurons of the reticular thalamic nucleus, take part in the generation of cortical spindle, delta and slow oscillations (Steriade et al. 1993 ; Steriade, 2006) . Interestingly, clinical quantitative EEG studies have demonstrated an increase in delta rhythm oscillation in schizophrenia (John et al. 2009 ; Karson et al. 1987 ). This abnormal increase was shown to significantly correlate with the Scale for the Assessment of Negative Symptoms in neuroleptic-naive first-episode patients (Gschwandtner et al. 2009 ). Taken together with the pathological changes of the thalamus in schizophrenia (Clinton & Meador-Woodruff, 2004) , changes in delta oscillation might be attributable to thalamo-cortical interactions. Due to the complex network architecture generating these rhythms, changes in oscillatory activity could be elicited at several, different brain regions and different levels of the neuronal network. For example, systemic administration of MK-801 could interfere with these circuits at multiple sites, leading to a less regular, low-frequency delta activity.
In order to interact with cortical delta oscillation in a more defined way, projection neurons from the MD were deactivated by lidocaine microinjection, which is known to block impulse generation and conduction by reducing the membrane permeability to sodium ions (Ritchie, 1975 ; Sarihi et al. 2003) . Interestingly, after lidocaine microinjection, qualitatively and quantitatively similar changes were observed in the mPFC LFP as seen after systemic MK-801 administration. The MD is known to reciprocally innervate the mPFC via glutamatergic synapses (Pirot et al. 1994) forming direct connections with both pyramidal cell and inhibitory interneurons. Consequently, the MD is in a position to exert dual influence on mPFC pyramidal cells by direct excitation and by indirect inhibition via local interneurons (Hull et al. 2009 ).
Simultaneous recordings of evoked potentials in the mPFC in response to electrical stimulation of the subiculum displayed short-term synaptic plasticity as revealed by PPF, in line with previous observations (Degenetais et al. 2003 ; Mulder et al. 1997) . Baseline control recording of cortical LFP oscillation and PPF values demonstrated a strong, significant correlation between these two measures. Urethane-anesthetized (n=11) 13.4¡0.5 (n=7) 44.5¡10 (n=7) Values are given as mean¡S.E.M., n is the number of EFPs used. No significant changes were found (paired, one-tailed t test). Table 3 . Lidocaine induced changes of the parameters of the N27 (1,2) component of the evoked field potential (EFP)
Values are given as mean¡S.E.M., n is the number of EFPs used. * Denotes significant change relative to controls (paired, one-tailed t test) ; for p values see text.
rats display spontaneous and cyclic alteration of brain states similar to natural sleep characterized by quantitative EEG signatures, and correlating with other physiological measures (Clement et al. 2008) . In our experiments a similar alteration between regular, high-frequency delta-characterized brain states and irregular, low-frequency delta-characterized brain states was observed. Thus, during regular, high delta activity a prominent, large PPF was present, which diminished parallel to shifting power from the high to less regular, low delta activity. This strong correlation was present even after systemic administration of MK-801 or de-activation of MD thalamo-cortical neurons -both manipulations leading to low delta activity. Since parallel changes in delta activity and PPF could be due to alterations in thalamo-cortical or/ and intracortical network activities, EFP responses to subiculum stimulations were closely analysed at baseline condition and after pharmacological manipulations (for a hypothetical scheme of ERP generation see Supplementary Fig. S5 ). Both NMDAR antagonists (MK-801 and PCP) and lidocaine microinjections reduced PPF by largely enhancing the amplitude of N27 1 component of the EFP in response to the first stimulus. In contrast, the amplitude and latency of the P12 1 deflection was reduced only by systemic administration of MK-801, but not lidocaine, suggesting that this component reflects monosynaptic NMDAR activations in the cortex in response to subiculum stimulation. Previous observations demonstrated that systemic administration of MK-801 preferentially blocks NMDARs at cortical interneurons leading to increased activity of pyramidal neurons (Homayoun & Moghaddam, 2007 ; Lisman et al. 2008 ; Sun et al. 2005) . Based on these findings, we suggest that the increase in N27 1 is due to a diminished inhibition after MK-801 administration. However, it seems that even indirect disruption of cortical, regular high-frequency delta activity would lead to disinhibition of pyramidal neurons and lead to an enhanced N27 1 response. Thus, lidocaine microinjection enhanced N27 1 amplitude as did MK-801 administration, since both treatments interfered with the cortical interneuron networks in a similar fashion, which is further reflected in identical changes in delta activity. Based on the above described observations, we propose a connection between the cortical state as reflected by the ongoing delta activity and cortical information processing, which is characterized by PPF (Abbott & Regehr, 2004) in our experiments. Although the experimental techniques used here allow us only to make a correlation-based conclusion, we suggest that systemic MK-801 administration, as well as local MD lidocaine microinjection result in a relative hypoglutamatergic state in the mPFC of urethaneanesthetized rats. Lack of glutamate on the one hand would hyperpolarize the LFP (Figs 1 and 6 ), resulting in a less regular, low-frequency LFP oscillation, and on the other, it would impact on the regulating action of local interneuron networks causing impaired response generation to subiculum stimulation. It should be noted that low-frequency stimulation of the subiculum-mPFC pathway was shown to be mainly activated through AMPA receptors (Jay et al. 1992) , and similarly, rapid excitation of interneurons necessary for feed-forward inhibition is largely NMDAR independent (Hull et al. 2009 ; Pouille et al. 2009 ). However, we suggest that in the present experiment, the hypoglutamatergic condition caused by blockade of NMDARs by MK-801, as well as local NMDAR blockade, is responsible for impaired interneuron function. A delicate balance of activation is needed in different neuron types of the mPFC to provide normal cortical function . Computational models have shown that an insufficient ratio between NMDA and GABA conductances (Lisman et al. 1998) or between NMDA and AMPA conductances Lisman et al. 1998) would result in a decrease in memory-related firing of pyramidal neurons and consequently in memory dysfunction. MK-801, via antagonizing NMDARs changes the balance between subtypes of excitatory amino-acid receptors, making it an attractive compound for modelling cognitive dysfunctions of schizophrenia. Therefore, in the present experiments it was tested whether changes in PPF and cortical delta activity could be reversed by the selective AMPAkine compound LY451395. Systemic administration of LY451395 fully reversed both MK-801-induced changes in PPF and cortical delta activity. Similarly, LY451395 was also active following lidocaine microinjection, overturning disruption of cortical, regular high delta activity and PPF. These findings indicate that amplification of AMPA current via positive allosteric modulation restores cortical delta activity and PPF. These findings also suggest that regular, high delta activity requires a substantial excitatory drive under anaesthesia, which was attenuated in our experiment either with systemic administration of MK-801 or blocking an extensive glutamateric projection from the thalamus with lidocaine. However, this relative hypoglutamateric state could be overcome by activation of AMPA receptors. In line with these observations, it has been recently reported that AMPAkines reverse NMDA-antagonist-induced deficits in preclinical models of cognition both in rats and non-human primates (Shaffer et al. 2009 ). Interestingly, there is growing evidence that phosphorylation of AMPA receptors is involved in the restoration of long-term potentiation of synapses at the hippocampus-PFC pathway following acute stress (Qi et al. 2009 ).
In summary, the current findings expand our understanding of the NMDAR hypofunction of schizophrenia, and provide a novel animal model for evaluating potential drug treatments addressing cognitive dysfunction of this disease. 
